Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) - Dermatology Notes
Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) - Dermatology Notes for Exam Preparation
9 min read
Definition: An immune complex-mediated inflammatory disorder characterized by neutrophilic infiltration and fibrinoid necrosis of the walls of small dermal blood vessels (capillaries and post-capillary venules). The term "leukocytoclastic" refers to nuclear dust from fragmented neutrophils.
Key Clinical Features:
Primary lesion: Palpable purpura (non-blanching, raised hemorrhagic papules) – the hallmark.
Distribution: Lower extremities (gravity-dependent) – legs, ankles, dorsal feet. May involve buttocks, trunk, upper extremities in severe or bedridden patients.
Morphology: Initially urticarial-like erythematous macules or papules → evolve over 24–48 hours into palpable purpura, vesicles, bullae, pustules, ulcers, or necrotic eschars.
Symptoms: Burning, pruritus, or pain (often burning sensation is characteristic).
Systemic involvement: May involve other organs (kidneys, joints, GI tract) depending on underlying disease (e.g., IgA vasculitis, ANCA-associated vasculitis).
Healing: Post-inflammatory hyperpigmentation; atrophic scars if ulceration occurs.
Associated Conditions/Diseases (critical to identify):
Infections (most common trigger): Group A streptococcus (upper respiratory), hepatitis B, hepatitis C, HIV, bacterial endocarditis, mycoplasma.
Drugs: Antibiotics (penicillins, cephalosporins, sulfonamides), NSAIDs, diuretics (furosemide, thiazides), phenytoin, allopurinol.
Autoimmune/connective tissue diseases: Systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren’s syndrome.
Systemic vasculitides:
IgA vasculitis (Henoch–Schönlein purpura) – LCV with IgA-dominant immune deposits.
ANCA-associated vasculitides (microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis) – may have cutaneous LCV as a manifestation.
Hypocomplementemic urticarial vasculitis – LCV with low C1q, C3, C4; associated with anti-C1q antibodies.
Malignancy: Lymphoproliferative disorders (especially hairy cell leukemia), solid tumors (lung, colon, renal).
Idiopathic (30–40%): No identifiable cause after thorough evaluation.
Prognosis:
Cutaneous-limited LCV: Excellent – self-limited over weeks to months (if trigger removed). May recur episodically.
With systemic involvement: Depends on underlying disease (e.g., renal involvement in IgA vasculitis, pulmonary-renal syndrome in ANCA-associated vasculitis).
Chronic recurrent LCV: Can persist for years; often idiopathic or associated with occult disease.
Differential Diagnosis:
Pigmented purpuric dermatoses (Schamberg disease): Non-palpable, cayenne pepper spots, no inflammation, no vasculitis on histology.
Thrombocytopenic purpura (ITP, TTP): Non-palpable, associated with low platelets, no leukocytoclasis on biopsy.
Disseminated intravascular coagulation (DIC): Acral necrosis, systemic illness, lab abnormalities.
Urticaria (ordinary): Blanching, transient (<24 hours per lesion), no palpable purpura, no vasculitis on biopsy.
Erythema multiforme: Target lesions, acral distribution, histology shows interface dermatitis (not vasculitis).
Meningococcemia: Febrile, septic, petechial/purpuric, Gram-negative cocci on blood smear.
Management with Rationale:
Identify and remove the trigger (most important): Stop offending drug; treat underlying infection (antibiotics if culture-proven – but avoid empirical antibiotics unless infection is confirmed, as they may be the trigger).
Supportive care: Leg elevation, compression stockings, emollients.
Antihistamines + NSAIDs: For mild, symptomatic (pruritus, burning, arthralgia) – but NSAIDs can themselves trigger LCV; use with caution.
Colchicine (0.6 mg twice daily): For chronic recurrent cutaneous LCV – reduces neutrophil chemotaxis and adhesion.
Dapsone (50–150 mg daily): Inhibits neutrophil myeloperoxidase and oxidative burst – effective for chronic LCV. Check G6PD before use.
Systemic corticosteroids (prednisone 0.5–1 mg/kg/day with taper): For severe cutaneous disease (ulceration, necrosis) or systemic involvement (renal, GI, pulmonary). Rationale: Rapid anti-inflammatory effect.
Immunosuppressants (azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide): Reserved for severe systemic vasculitis or steroid-refractory disease (usually managed with rheumatology).
Avoid corticosteroids for mild cutaneous-limited LCV – side effects outweigh benefits.
Histopathology
1. FOUNDATIONS (First Principles)
Normal post-capillary venule: Located in the superficial and mid-dermis. Endothelial cells line the lumen; pericytes surround the endothelium; basement membrane is intact. Function: Exchange of nutrients, waste, and immune cells.
Normal neutrophil: Circulating polymorphonuclear leukocyte with segmented nucleus. Functions: Phagocytosis, degranulation, neutrophil extracellular trap (NET) formation.
Normal vessel wall: Type IV collagen, laminin, proteoglycans. Endothelial cells express adhesion molecules (E-selectin, ICAM-1, VCAM-1) when activated.
Immune complex (IC): Antigen–antibody complex. Normally cleared by the reticuloendothelial system. Small ICs (antigen excess) deposit in vessel walls.
2. INITIATING EVENT
Trigger (infection, drug, autoimmune, malignancy) leads to antigen excess and formation of circulating immune complexes (or in situ immune complex formation).
Antigen is often unknown (exogenous: microbial, drug; endogenous: DNA, IgG).
Immune complexes deposit in the subendothelial space of post-capillary venules.
3. PATHOGENESIS
Immune complexes deposit in vessel wall → activate the classical complement pathway (C1q → C4 → C2 → C3 convertase).
C3 activation generates C3a and C5a (anaphylatoxins) – potent chemoattractants for neutrophils.
C5a upregulates endothelial adhesion molecules (E-selectin, ICAM-1) and binds to C5a receptors on neutrophils.
Neutrophils adhere to endothelium (rolling → firm adhesion via β2 integrins) and migrate through vessel wall (diapedesis).
Neutrophils attempt to phagocytose immune complexes → release lysosomal enzymes (elastase, collagenase, myeloperoxidase, cathepsin G) and reactive oxygen species.
Enzymes digest the vessel wall basement membrane and extracellular matrix → fibrinoid necrosis (eosinophilic, amorphous debris in vessel wall).
Neutrophils undergo apoptosis and necrosis → nuclear fragmentation (karyorrhexis) = leukocytoclasis.
Fibrin leaks into the vessel wall and perivascular space → fibrin deposition.
Endothelial damage → red blood cell extravasation → purpura.
Why post-capillary venules? They have slower blood flow (longer immune complex contact time), higher permeability, and different adhesion molecule expression compared to arterioles.
4. HISTOPATHOLOGY EXPLAINED
Low power:
Superficial and mid-dermal perivascular infiltrate (involves post-capillary venules).
Leukocytoclasis – abundant nuclear dust (fragmented, pyknotic neutrophil nuclei scattered around vessels) – the defining feature.
Fibrinoid necrosis – vessel walls appear pink, smudgy, and amorphous (loss of normal endothelial lining).
Erythrocyte extravasation – red blood cells outside vessels (purpura).
Vessel wall thickening and endothelial swelling.
High power:
Neutrophils dominate the infiltrate (early lesion). Later lesions may show lymphocytes and histiocytes.
Karyorrhexis – nuclear dust = leukocytoclasis.
Fibrin deposition – bright eosinophilic, stringy or globular material within and around vessel walls.
Endothelial cells – swollen, plump, may be absent in areas of necrosis.
Perivascular edema – pale, clear space around vessels.
Variable eosinophils – if present, suggest drug-induced LCV or eosinophilic granulomatosis with polyangiitis (EGPA).
Variable lymphocytes – in later or resolving lesions.
Dermis (surrounding):
Papillary dermal edema (may form subepidermal vesicles or bullae if severe).
No epidermal involvement (except secondary changes – necrosis from ischemia if severe).
Why this appearance:
Leukocytoclasis – Neutrophils die after degranulation; their nuclei fragment. This is the histologic signature of LCV.
Fibrinoid necrosis – Fibrin from plasma leaks into damaged vessel wall + necrotic cellular debris + immune complexes. The bright pink color on H&E is due to fibrin.
Erythrocyte extravasation – Damaged endothelium and vessel wall allow RBCs to leak out.
Perivascular edema – Increased vascular permeability from C3a, C5a, and histamine.
5. NAMING LOGIC & TERMINOLOGY
Leukocytoclastic – From leuko- (white blood cell, specifically neutrophil) + -clastic (breaking) + -ic (pertaining to). Refers to nuclear dust from fragmented neutrophils.
Vasculitis – Inflammation of blood vessels.
Fibrinoid necrosis – Resembles fibrin (fibrin-like) + necrosis (tissue death). The vessel wall appears like amorphous pink fibrin.
Palpable purpura – Purpura (hemorrhage into skin) that is palpable (raised) due to perivascular inflammation and edema.
Karyorrhexis – Nuclear fragmentation (karyon = nucleus, rhexis = rupture).
6. STAINING & MARKERS
H&E: Diagnostic as described above. Requires a deep enough biopsy (4–6 mm punch) to include superficial and mid-dermis. Avoid incisional biopsy of ulcerated center (non-diagnostic – necrosis obscures vessels).
Special stains:
PAS (periodic acid–Schiff): Highlights thickened, disrupted, or duplicated basement membrane of affected vessels.
Fibrin stain (phosphotungstic acid hematoxylin – PTAH): Confirms fibrin deposition in vessel walls (not routinely needed).
Immunofluorescence (direct immunofluorescence – DIF) – essential for subclassification:
IgA vasculitis (Henoch–Schönlein purpura): Granular IgA deposits in vessel walls (often with C3, fibrin). This is the only LCV where IgA predominates.
IgG/IgM-dominant LCV (most common): Granular IgG, IgM, and C3 in vessel walls.
Hypocomplementemic urticarial vasculitis: Granular C1q, C3, IgG, IgM; often with anti-C1q antibodies (serum).
Pauci-immune LCV (ANCA-associated): Minimal or no immune deposits (vessel wall necrosis but little Ig/complement). Seen in microscopic polyangiitis, granulomatosis with polyangiitis (GPA), EGPA.
Fibrinogen: Bright staining outlining vessel walls (fibrinoid necrosis).
Immunohistochemistry (IHC) – not routinely diagnostic:
CD68: Stains macrophages/histiocytes (in later lesions, as neutrophils are replaced by macrophages).
Myeloperoxidase (MPO): Positive in neutrophils (confirms neutrophil origin of leukocytoclasis).
CD3, CD20: For lymphocyte phenotyping (if lymphocytic vasculitis suspected – rare).
Serologic correlation (not histology but essential for diagnosis):
ANCA (c-ANCA/PR3, p-ANCA/MPO), cryoglobulins, complement (C3, C4, CH50), ANA, RF, hepatitis B/C serologies, blood cultures.
Why DIF is critical: DIF distinguishes immune-complex mediated LCV (IgG/IgM/IgA) from pauci-immune (ANCA-associated) and identifies IgA vasculitis (which has different prognosis and management).
7. TEMPORAL EVOLUTION
Early lesion (urticarial, <24 hours): Neutrophilic infiltrate around vessels, endothelial swelling, minimal fibrinoid necrosis, minimal leukocytoclasis. May be subtle – repeat biopsy if early.
Established lesion (palpable purpura, 24–72 hours): Florid leukocytoclasis, fibrinoid necrosis, erythrocyte extravasation, neutrophilic infiltrate. This stage is most diagnostic.
Late lesion (resolving, >72 hours to weeks): Neutrophils replaced by lymphocytes and histiocytes (healing phase). Leukocytoclasis is less prominent. Fibrinoid necrosis resolves. This stage can mimic lymphocytic vasculitis or perivascular dermatitis – biopsy of a fresh lesion is essential.
Healed lesion (post-inflammatory hyperpigmentation): Hemosiderin-laden macrophages (iron deposition), fibrosis, no active vasculitis.
Board critical point: Biopsy early palpable purpura (24–48 hours). If you biopsy a late lesion, you may see only lymphocytic infiltrate and miss the diagnosis.
8. PATTERN RECOGNITION & DIAGNOSTIC LOGIC
Pattern: Superficial and mid-dermal perivascular neutrophilic infiltrate + leukocytoclasis + fibrinoid necrosis + erythrocyte extravasation.
Diagnostic pathway (integrating histology, DIF, and serology):
H&E shows LCV + DIF shows granular IgA deposits → IgA vasculitis (Henoch–Schönlein purpura) .
H&E shows LCV + DIF shows granular IgG/IgM/C3 + low serum C3/C4 → Hypocomplementemic urticarial vasculitis (or SLE-associated).
H&E shows LCV + DIF shows granular IgG/IgM/C3 + normal complement → Idiopathic or infection/drug-induced LCV.
H&E shows LCV + DIF pauci-immune (no Ig/complement) + serum ANCA positive → ANCA-associated vasculitis (GPA, MPA, EGPA) – look for systemic features.
H&E shows LCV + eosinophils prominent + DIF pauci-immune + p-ANCA/MPO positive → Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) .
H&E shows LCV + cryoglobulins positive + hepatitis C serology positive → Cryoglobulinemic vasculitis (often shows more intravascular thrombi).
H&E shows LCV + DIF negative + no systemic features + self-limited → Cutaneous-limited LCV (idiopathic) .
Key discriminator from other vasculitides:
Leukocytoclastic vasculitis – small vessels (capillaries, post-capillary venules), neutrophils, leukocytoclasis, fibrinoid necrosis.
Lymphocytic vasculitis (e.g., pigmented purpuric dermatosis, erythema elevatum diutinum) – lymphocytes dominate, no leukocytoclasis (early erythema elevatum diutinum has neutrophils but later fibrosis).
Polyarteritis nodosa (PAN) – medium vessels (muscular arteries), shows fibrinoid necrosis but no leukocytoclasis; involves deep dermis and subcutis.
Thrombotic vasculopathy (calciphylaxis, warfarin necrosis, antiphospholipid syndrome) – no inflammation (or minimal), thrombi occlude vessels.
9. CLINICO-PATHOLOGICAL CORRELATION
Palpable purpura → Erythrocyte extravasation (purpura) + perivascular edema and inflammation (palpable).
Burning sensation → Neutrophil degranulation releases mediators (bradykinin, prostaglandins, leukotrienes) that stimulate nerve endings.
Lower extremity predilection → Gravity-dependent stasis → slower blood flow → longer immune complex contact time with venular endothelium.
Urticarial appearance before purpura → Early lesion shows edema and neutrophil infiltration without yet enough RBC extravasation to cause visible purpura.
Ulceration/necrosis → Severe fibrinoid necrosis and vessel occlusion → ischemia.
Lesions resolve with hyperpigmentation → Hemosiderin-laden macrophages (from extravasated RBCs) remain after vasculitis resolves.
Systemic symptoms (arthralgia, abdominal pain, hematuria) → Immune complex deposition in joints, GI tract, renal glomeruli (same pathogenesis as skin).
10. EXAM-FOCUSED INSIGHTS
Palpable purpura + biopsy showing leukocytoclasis = LCV until proven otherwise – Board classic.
Leukocytoclasis is the defining histologic feature – Nuclear dust = diagnostic. If you don’t see it, consider another diagnosis or re-biopsy.
Biopsy timing is critical – Biopsy a lesion at 24–48 hours (established palpable purpura). Too early (urticarial) – may miss leukocytoclasis. Too late (resolving) – lymphocytes dominate, may mimic other conditions.
Direct immunofluorescence (DIF) is essential – Distinguishes IgA vasculitis (IgA deposits) from other immune-complex LCV (IgG/IgM) from pauci-immune (ANCA-associated).
Do NOT mistake LCV for thrombotic vasculopathy – LCV has inflammation; thrombotic conditions have bland thrombi without vessel wall inflammation.
Idiopathic LCV is a diagnosis of exclusion – Always search for trigger (drugs, infection, autoimmune, malignancy, cryoglobulins, hepatitis B/C, ANCA-associated disease).
First-line treatment for cutaneous-limited LCV is trigger removal + supportive care – Not corticosteroids (unless severe or systemic).
Colchicine and dapsone are second-line for chronic recurrent LCV – Board favorite for management of chronic disease.
Corticosteroids reserved for severe cutaneous (ulceration/necrosis) or systemic involvement – Do not use steroids for mild, self-limited LCV.
Hypocomplementemia in LCV – Suggests SLE, hypocomplementemic urticarial vasculitis, or cryoglobulinemia. Normal complement is more common (idiopathic, drug, infection).
Eosinophils in LCV – Think drug-induced LCV or EGPA (Churg–Strauss).
Must-Know Board Exam Questions & Answers
Q1: A 45-year-old woman presents with palpable purpura on the lower legs. Biopsy shows a superficial perivascular neutrophilic infiltrate with nuclear dust, fibrinoid necrosis, and red blood cell extravasation. What is the diagnosis, and what is the histologic finding that defines it?
A: Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis). The defining histologic feature is leukocytoclasis (nuclear dust from fragmented neutrophils).
Q2: What is the most common clinical presentation of leukocytoclastic vasculitis?
A: Palpable purpura (non-blanching, raised hemorrhagic papules) distributed on the lower extremities.
Q3: A patient has recurrent palpable purpura. Direct immunofluorescence (DIF) of a skin biopsy shows granular IgA deposits in vessel walls. What is the diagnosis?
A: IgA vasculitis (Henoch–Schönlein purpura).
Q4: What is the optimal timing for skin biopsy in suspected leukocytoclastic vasculitis?
A: 24 to 48 hours after lesion onset (established palpable purpura). Too early (urticarial) may miss leukocytoclasis; too late (resolving) shows lymphocyte predominance and obscures the diagnosis.
Q5: A biopsy of a purpuric lesion shows perivascular lymphocytes without leukocytoclasis or fibrinoid necrosis. What are the two most likely diagnostic possibilities?
A: (1) Resolving leukocytoclastic vasculitis (late-stage healing) – re-biopsy a fresh lesion; (2) Lymphocytic vasculitis (pigmented purpuric dermatosis, erythema elevatum diutinum, or other diagnosis).
Q6: What is the first step in managing a patient with newly diagnosed leukocytoclastic vasculitis?
A: Identify and remove the trigger – stop offending drugs, treat underlying infection, evaluate for systemic disease (autoimmune, hepatitis B/C, ANCA-associated vasculitis, malignancy).
Q7: Name two medications used for chronic recurrent cutaneous leukocytoclastic vasculitis (without systemic involvement) and their mechanisms.
A: Colchicine (reduces neutrophil chemotaxis and adhesion) and dapsone (inhibits neutrophil myeloperoxidase and oxidative burst). Check G6PD before dapsone.
Q8: A patient with leukocytoclastic vasculitis on biopsy has serum cryoglobulins positive and hepatitis C antibodies positive. What is the most likely underlying disease?
A: Cryoglobulinemic vasculitis (type II or III mixed cryoglobulinemia) associated with hepatitis C.
Q9: What is the role of systemic corticosteroids in leukocytoclastic vasculitis?
A: Reserved for severe cutaneous disease (ulceration, necrosis) or systemic involvement (renal, GI, pulmonary). Not indicated for mild, self-limited, cutaneous-only LCV.
Q10: A skin biopsy shows leukocytoclastic vasculitis with prominent eosinophils, and serum p-ANCA (MPO) is positive. What systemic vasculitis should be suspected?
A: Eosinophilic granulomatosis with polyangiitis (EGPA, Churg–Strauss syndrome).